Home Newsfeeds Baird Maintains Outperform on Keysight Technologies, Raises Price Target to $190

Baird Maintains Outperform on Keysight Technologies, Raises Price Target to $190

Baird analyst Richard Eastman maintains Keysight Technologies (NYSE:KEYS) with a Outperform and raises the price target from $169 to $190.

byBenzinga Newsdesk

August 18, 2022

1 minute read

Baird analyst Richard Eastman maintains Keysight Technologies (NYSE:KEYS) with a Outperform and raises the price target from $169 to $190.

Enhabit Sees FY23 EPS $0.28-$0.46 Vs $0.65 Est.; Revenue $1.057B-$1.065B Vs $1.11B Est.

By Happy Mohamed

August 9, 4:33 PM

GUIDANCE The Company revised its full-year 2023 guidance as follows: ($ in millions, except per share data) Full-Year 2023 2023

EHAB

Asia Markets Surge Following Wall Street Earnings Boost — Japan, Australia Lead Pack

By Bhavik Nair

July 20, 3:09 AM

Asian markets surged Wednesday morning with Japan’s Nikkei leading the pack after Wall Street witnessed heavy buying, the day before, led by upbeat corporate earnings and expectations of gas supply resumption to Europe from Russia helped calm investor angst.

NPSCY

Goldman Sachs Upgrades Chart Industries to Buy, Raises Price Target to $259

By Benzinga Newsdesk

September 15, 6:22 AM

Goldman Sachs analyst Atidrip Modak upgrades Chart Industries (NYSE:GTLS) from Neutral to Buy and raises the price target from $200 to $259.

GTLS

Solaris Biotech And Wildtype Announce Agreement For Large-Scale Bioreactors For Cultivated Seafood Production NOTE: Solaris Has Been A Part Of Donaldson Company And Its Expansion Into Life Sciences

By Benzinga Newsdesk

November 15, 1:34 PM

Solaris and Wildtype signed an agreement to collaboratively develop a new generation of bioreactors to foster large-scale production of cultivated seafood. Bioreactors are one of the most important pieces of equipment

DCI

Baird Maintains Outperform on Keysight Technologies, Raises Price Target to $190

Related Posts

Enhabit Sees FY23 EPS $0.28-$0.46 Vs $0.65 Est.; Revenue $1.057B-$1.065B Vs $1.11B Est.

Asia Markets Surge Following Wall Street Earnings Boost — Japan, Australia Lead Pack

Goldman Sachs Upgrades Chart Industries to Buy, Raises Price Target to $259

Solaris Biotech And Wildtype Announce Agreement For Large-Scale Bioreactors For Cultivated Seafood Production NOTE: Solaris Has Been A Part Of Donaldson Company And Its Expansion Into Life Sciences